Menu

Doctor Who Blocked Thalidomide Dies

Frances Oldham Kelsey, a physician who halted use of a drug that caused birth defects in babies, has passed away at age 101.

Aug 11, 2015
Kerry Grens

WIKIMEDIA, THE US FOOD AND DRUG ADMINISTRATIONA physician and former medical reviewer for the US Food and Drug Administration (FDA), Frances Oldham Kelsey died last week (August 7). She was 101.

Kelsey is highly regarded for her work in denying approval for the medication thalidomide, which caused birth defects in babies when taken by pregnant women.

“Her exceptional judgment in evaluating a new drug for safety for human use has prevented a major tragedy of birth deformities in the United States,” President John F. Kennedy said of Kelsey, The New York Times reported.

Kelsey was a new medical officer at the FDA in 1960 when the application for thalidomide approval came across her desk. The medication was already used in Europe to treat nausea in pregnant women, but Kelsey was not convinced the treatment was safe. Her hesitation paid off, and evidence of the drug’s hazards began accumulating in the early 1960s.

The tragedy of thalidomide—and Kelsey’s demand for safety data—inspired new laws around the approval of new drugs and the evidence required to support their safety and efficacy.

Kelsey spent 45 years at the FDA, including leading the Office of Scientific Investigations. She “helped rewrite the nation’s medical-testing regulations, strengthening protections for people and against medical conflicts of interest,” the New York Times noted. “The rules have been adopted worldwide.”

“She had a huge effect on the regulations adopted in the 1960s to help create the modern clinical trial system,” Harvard University’s Daniel Carpenter, who wrote a book about the history of the FDA, told The Washington Post. “She may have had a bigger effect after thalidomide than before.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!